Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2124399 | European Journal of Cancer | 2009 | 9 Pages |
Abstract
Lack of TIMP-1 tumour cell immunoreactivity seems to predict a favourable effect of epirubicin-containing adjuvant therapy in primary breast cancer. However, an independent study is awaited to validate the potential predictive value of TIMP-1 immunoreactivity.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Gro L. Willemoe, Pernille B. Hertel, Annette Bartels, Maj-Britt Jensen, Eva Balslev, Birgitte B. Rasmussen, Henning Mouridsen, Bent Ejlertsen, Nils Brünner,